Age-Related Macular Degeneration

In this episode, Veeral Sheth, MD, sits down with Jay Duker, MD for a discussion on his storied career, fostering relationships with industry, and the current technology being worked on at Eyepoint Pharmaceuticals for retinal disorders.

The analysis indicated a 41.4% decrease in the number of OR visits after the COVID-19 pandemic with a parallel decrease in the number of intravitreal injections, compared to the pre-COVID period.

More data is needed to determine whether low-dose levodopa use reduces conversion to neovascular AMD.

Modified production of abicipar was linked to a moderately lower incidence and severity of IOI in nAMD eyes compared with Phase 3 results, but further reductions in IOI are required to match the incidence rates of other anti-VEGF therapies.

According to a release from Oculis, the trial met its stage 1 objective of validating the dosing regimen designed to optimize the efficacy potential of OCS-01 with statistical significance.

The structure of the retinal vasculature may be able to predict the initial treatment response to intravitreal therapy in patients with treatment-naïve nAMD.

An economic evaluation of the SCORE2 trial indicates aflibercept treatment was unlikely to meet most accepted standards of cost-effectiveness, due to little difference in visual acuity outcomes and a large cost differential compared with bevacizumab.

A recent analysis of patients with AMD detected no significant associations between AMD-associated variants and hemopexin levels.

A post-hoc analysis of the HARBOR trial suggests MNV type 3 was a strong risk factor for new macular atrophy development at month 24 in ranibizumab-treated eyes with nAMD.

In this episode, Charles Wykoff, MD, PhD joins Dr. Sheth to provide insight into the recent landmark approval of pegcetacoplan injection (SYFOVRE™) for geographic atrophy, how clinical practice has changed as a result, and both the early struggles with and optimism for an ever-changing treatment landscape.

Retrospective data suggest a treat-and-extend regimen using brolucizumab is effective for improving outcomes in eyes with exudative AMD refractory to aflibercept.

Intravitreal brolucizumab and aflibercept in eyes with nAMD were each linked to a significant decrease in the ocular blood flow 30 minutes after injection.

Alterations in the compositions and metabolic functions of intestinal microbiota between AMD patients and healthy controls may help elucidate specific targets for AMD treatment.

A single-center study reports no significant difference in global peripapillary RNFL thickness in eyes treated with intravitreal brolucizumab during a short-term follow-up period after injection.

The 6-month RCT investigating submacular hemorrhage secondary to nAMD found that both treatment modalities showed clinical improvement of VA, but surgery did not provide a superior visual gain.

Each month, our editorial staff compiles a recap of the top news in ophthalmology from the past month. Our April 2023 month-in-review features data on the association between social determinants of health and vision loss, preferences for AMD monitoring, and the launch of a new multimedia series.

At ARVO 2023, 24-month data suggests the change from baseline in GA lesion growth consistently favored pegcetacoplan vs. sham across subgroups in DERBY and OAKS trials.

An analysis of the TENAYA/LUCERNE presented at ARVO 2023 suggests faricimab more rapidly improved anatomic outcomes in patients with nAMD compared to aflibercept.

A posthoc analysis of the phase 2 CANDELA study presented at ARVO 2023 suggests aflibercept 8 mg improved visual and anatomical outcomes compared with aflibercept 2 mg in eyes with nAMD.

Presented at ARVO 2023, the nationwide data on nAMD real-world management in France suggest a discrepancy between avoiding the undertreatment of nAMD and the real-world management of the disease.

New research presented at ARVO 2023 suggests intravitreal brolucizumab led to the resolution of IRF and SRF in a significant number of patients with nAMD previously unresponsive to anti-VEGF therapy.

In an interview at ARVO 2023, Danzig discusses the post-hoc analysis from the GATHER trials, showing that a reduced rate of vision loss in patients receiving avacincaptad pegol was correlated with reduced GA growth.

As part of our ARVO 2023 coverage, Dr. Sheth sat down with Pravin Dugel, MD, President of Iveric Bio to discuss avacincaptad pegol for geographic atrophy and a look back at Dr. Dugel's career and his transition into industry.

In the inaugural episode of "New Insight with Veeral Sheth, MD," Dr. Sheth speaks with Arshad Khanani, MD on exciting developments from 2022, and a look at both the conference and treatment landscape unfolding in 2023.

An analysis of the HIT study suggested eyes with AMD treated with hydroxychloroquine experienced less growth and less drusen formation than those treated with control at two-year follow-up.

At 1-year follow-up, intravitreal aflibercept and brolucizumab reportedly improved vision in treatment-naïve patients with submacular hemorrhage secondary to AMD, unless vitreous hemorrhage developed.

Retrospective analyses suggest the feasibility of using FAF images, OCT volumes to predict GA growth rates and area using a multitask deep learning approach.

In the case of another situation similar to COVID-19 home confinement, the majority of the patients with nAMD in a Swiss study would prefer a visit to the clinic over telemedicine to monitor their disease.

Compared with individuals with normal glycemic status, a recent analysis found AMD risk increased with higher glycemic status and longer duration of diabetes.

Announced today by Horizon Therapeutics, the positive and statistically significant data supports the efficacy of teprotumumab across a spectrum of patients with TED regardless of disease activity or duration.